Global Pharma Grade Polyvinylpyrrolidone Market Strategic Research Report

Scope of the Report

The global Pharma Grade Polyvinylpyrrolidone market size is predicted to grow from US$ 494 million in 2025 to US$ 698 million in 2032; it is expected to grow at a CAGR of 5.1% from 2026 to 2032.

Pharma Grade Polyvinylpyrrolidone (NVP) is a non-ionic, water-soluble polymeric pharmaceutical excipient obtained by polymerizing N-vinylpyrrolidone as a monomer. Its pharmacopoeia name is usually Povidone. Its core characteristics are good water solubility, good film-forming properties, strong adhesiveness, and the ability to form hydrogen bonds or complex structures with some poorly soluble drugs, thereby improving granulation, tablet strength, dissolution, dispersion, and stability.

The upstream core is the N-vinylpyrrolidone (NVP) monomer. The upstream components typically involve γ-butyrolactone, 2-pyrrolidone, acetylene, or related vinyl groups, as well as ammonia, hydrogen, water, initiators, solvents, and refining auxiliaries. The purity of the NVP monomer directly affects the control of residual monomers, color, peroxides, and odor in PVP, and is a key factor differentiating pharmaceutical-grade products from ordinary industrial-grade products. After polymerization, residue removal, filtration, concentration, spray drying, sieving, and packaging are required. The production process demands a high level of cleanliness, microbial control, and batch consistency.

In 2025, global sales of pharmaceutical-grade polyvinylpyrrolidone are estimated at 40,000 tons, with an average market price of approximately US$12,000 per ton. The gross profit margin of major producers in the industry is estimated at 30%–45%.

Pharma grade polyvinylpyrrolidone (PVP) is a mature pharmaceutical excipient. Growth in the industry primarily comes from demand in oral solid dosage forms, generic drug consistency evaluation, solubilization of poorly soluble drugs, solid dispersions, wet granulation, and complex formulation development. In particular, PVP products like K30 and K90 offer stable applications in adhesion, film formation, solubilization, and stability. Once pharmaceutical companies complete formulation validation and supplier audits, replacement costs are high, thus high-quality suppliers exhibit strong customer loyalty. The main industry obstacle lies in the large production capacity of ordinary industrial-grade PVP. Pharmaceutical-grade products require long-term pharmacopoeia compliance, impurity control, batch stability, excipient registration, and customer validation, making it difficult to truly enter the core supply chains of pharmaceutical companies. International companies such as BASF and Ashland still hold advantages in high-end excipient quality systems and brand recognition.

This report presents a comprehensive overview of the global Pharma Grade Polyvinylpyrrolidone market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• K17
• K25
• K30
• K90
• Other

Segment by Molecular Weight

• Low Molecular Weight
• Medium Molecular Weight
• High Molecular Weight

Segment by Morphology

• Standard Type
• Micro Powder Type

Segment by Application

• Oral Preparations
• Injectable Preparations
• Topical Preparations
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pharma Grade Polyvinylpyrrolidone market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Oral Preparations, Injectable Preparations, Topical Preparations evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact